Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 74% Improvement Relative Risk Lauriola et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 360 patients in Italy Lower mortality with HCQ (p=0.001) Lauriola et al., Clinical and Translational Scie.., doi:10.1111/cts.12860 Favors HCQ Favors control
Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in COVID-19 patients
Lauriola et al., Clinical and Translational Science, doi:10.1111/cts.12860
Lauriola et al., Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in COVID-19 patients, Clinical and Translational Science, doi:10.1111/cts.12860
Sep 2020   Source   PDF  
  All Studies   Meta
Retrospective 377 patients, 73% reduction in mortality with HCQ+AZ, adjusted hazard ratio HR 0.27 [0.17-0.41]. Mean age 71.8. No serious adverse events. Subject to incomplete adjustment for confounders.
risk of death, 73.5% lower, HR 0.27, p < 0.001, treatment 102 of 297 (34.3%), control 35 of 63 (55.6%), NNT 4.7, adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lauriola et al., 14 Sep 2020, retrospective, Italy, peer-reviewed, mean age 71.8, 10 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Citation: Clin Transl Sci (2020) 13, 1071–1076; doi:10.1111/cts.12860 ARTICLE Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19 Marinella Lauriola1,†, Arianna Pani2,†, Giovanbattista Ippoliti3, Andrea Mortara4, Stefano Milighetti3, Marjieh Mazen3, Gianluca Perseghin3,5, Daniele Pastori6,*, Paolo Grosso7,‡ and Francesco Scaglione2,‡ Conflicting evidence regarding the use of hydroxychloroquine (HCQ) and azithromycin for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection do exist. We performed a retrospective single-center cohort study including 377 consecutive patients admitted for pneumonia related to coronavirus disease 2019 (COVID-19). Of these, 297 were in combination treatment, 17 were on HCQ alone, and 63 did not receive either of these 2 drugs because of contraindications. The primary end point was in-hospital death. Mean age was 71.8 ± 13.4 years and 34.2% were women. We recorded 146 deaths: 35 in no treatment, 7 in HCQ treatment group, and 102 in HCQ + azithromycin treatment group (log rank test for Kaplan–Meier curve P < 0.001). At multivariable Cox proportional hazard regression analysis, age (hazard ratio (HR) 1.057, 95% confidence interval (CI) 1.035–1.079, P < 0.001), mechanical ventilation/continuous positive airway pressure (HR 2.726, 95% CI 1.823–4.074, P < 0.001), and C reactive protein above the median (HR 2.191, 95% CI 1.479–3.246, P < 0.001) were directly associated with death, whereas use of HCQ + azithromycin (vs. no treatment; HR 0.265, 95% CI 0.171–0.412, P < 0.001) was inversely associated. In this study, we found a reduced in-hospital mortality in patients treated with a combination of HCQ and azithromycin after adjustment for comorbidities. A large randomized trial is necessary to confirm these findings. Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? ✔ Few clinical evidences are available regarding the use of hydroxychloroquine (HCQ) and azithromycin for patients with coronavirus disease 2019 (COVID-19), despite that this combination has been the most used worldwide so far. WHAT QUESTION DID THIS STUDY ADDRESS? ✔ This study evaluates the relationship between combination therapy of HCQ and azithromycin and in-hospital mortality in patients with severe acute respiratory syndrome coronavirus 2 infection-related pneumonia. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is spreading worldwide since December 2019 and still no proven effective therapy has been found. First therapy proposed to treat coronavirus disease 2019 (COVID-19) has been the association of lopinavir-ritonavir, a protease inhibitor approved for HIV infection. However, Cao et al. observed no benefit comparing lopinavir-ritonavir treatment of hospitalized patients with severe COVID-19,1 and this treatment is currently not † WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? ✔ This study reveals an inverse relation between HCQ and azithromycin use and in-hospital mortality, when compared with HCQ alone or no treatment. The combination was safe as patients with contraindications were excluded. HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? ✔ This efficacy analysis on a large sample that shows the potential efficacy of the combination of HCQ and azithromycin in COVID-19. recommended. Currently, only remdesivir has been approved for COVID-19 treatment, as it reduced recovery time by 4 days in..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop